Clinical Trials · NCT03895463

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Name: Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnN/ALanreotide

Phase: N/A
Recruitment status: Withdrawn
Sponsor: Ipsen
Enrollment: 0
Start date: Aug 2019
Locations: 11 sites, Poland
Primary endpoint: Progression-Free Survival (PFS)

View Lanreotide compound reference